Trimetazidine to prevent myocardial injury or nephropathy in diabetic, renally-impaired patients undergoing percutaneous coronary intervention.
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2015
At a glance
- Drugs Trimetazidine (Primary)
- Indications Myocardial disorders; Renal impairment
- Focus Adverse reactions; Therapeutic Use
- 26 Nov 2015 New trial record